Attorney Docket No.

017753-200



Filing Date:

Sir:

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of

Manuel Rosa-Calatrava et al.

Application No.: 10/520,626 <

January 10, 2005

Group Art Unit:

Examiner:

Confirmation No.: 9366

Title: MODIFIED ADENOVIRAL FIBER WITH ABLATED BINDING TO CELLULAR RECEPTORS

AMENDMENT/REPLY TRANSMITTAL LETTER

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Enc	losed is a reply for the above-identified patent application.
	A Petition for Extension of Time is also enclosed.
	Terminal Disclaimer(s) and the \$\infty\$\$ \$65.00 (2814) \$\infty\$\$ \$130.00 (1814) fee per Disclaimer due under 37 C.F.R. \(\) 1.20(d) are also enclosed.
\boxtimes	Also enclosed is/are
	Copy of Notification to Comply with Requirements for Patent Applications Containing Nucleotide and/or Amino Acid Sequence Disclosures Declaration 1.821-1.825 Submission of Documents (Sequence Listing) Computer Readable Form Sequence Listing on paper and diskette
	Small entity status is hereby claimed.
	Applicant(s) requests continued examination under 37 C.F.R. § 1.114 and enclose the \$395 00 (2801) \$790.00 (1801) fee due under 37 C.F.R. § 1.17(e).
	Applicant(s) requests that any previously unentered after final amendments <u>not</u> be entered. Continued examination is requested based on the enclosed documents identified above.
	Applicant(s) previously submitted
	for which continued examination is requested.
	Applicant(s) requests suspension of action by the Office until at least, which does not exceed three months from the filing of this RCE, in accordance with 37 C.F.R. § 1.103(c). The required fee under 37 C.F.R. § 1.17(i) is enclosed.
	A Request for Entry and Consideration of Submission under 37 C.F.R. § 1.129(a) (1809/2809) is also enclosed.

Application No. __10/520,626

■ No additional claim fee is required.

An additional claim fee is required, and is calculated as shown below.

AMENDED CLAIMS									
·	No. of Claims	Highes of Cla Previo Paid	aims usly	•	Extra Claims		Ra	te	Additional Fee
Total Claims	43	MINUS	20	=	23	×	\$50.00	(1202) =	\$ 1150.00
Independent Claims	1	MINUS	3	=	0	×	\$200.00	(1201) =	\$ 0.00
If Amendment adds n	nultiple depen	dent claim	s, add	d \$	360.00 (1203)				
Total Claim Amendment Fee						\$ 1,150.00			
Small Entity Status claimed - subtract 50% of Total Claim Amendment Fee					\$ 0.00				
TOTAL ADDITIONAL CLAIM FEE DUE FOR THIS AMENDMENT						\$ 1,150.00			

X	A check i	n the amount of	\$ 1,150.00	_ is enclosed for the fee due
	Charge _	to	Deposit Acc	ount No. 02-4800.
	Charge _	to	credit card.	Form PTO-2038 is attached.

The Director is hereby authorized to charge any appropriate fees under 37 C.F.R. §§ 1.16, 1.17, 1.20(d) and 1.21 that may be required by this paper, and to credit any overpayment, to Deposit Account No. 02-4800. This paper is submitted in duplicate.

Respectfully submitted,

BUCHANAN INGERSOLL PC

P.O. Box 1404 Alexandria, Virginia 22313-1404 (703) 836-6620

Date: December 19, 2005

Ву

Registration No. 45,904

12/22/2005 GFREY1

00000095 10520626

01 FC:1615

1150.00 OP



Rec'd PCT/PTC 1 DEC 2005

Attorney's Docket No. 032751-091

Patent *** 2751-091

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of	MAIL STOP MISSING PARTS
Manuel Rosa-Calatrava et al.	Group Art Unit:
Application No.: 10/520,626	Examiner:
Filed: January 10, 2005	Confirmation No.: 9366
For: MODIFIED ADENOVIRAL FIBER WITH ABLATED BINDING TO CELLULAR RECEPTORS (As Amended))))

SUBMISSION OF DOCUMENTS (SEQUENCE LISTING)

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

In response to the Notification To Comply With Requirements For Patent Applications Containing Nucleotide Sequence And/Or Acid Sequence Disclosures mailed October 17, 2005, Applicants enclose a Sequence Listing, along with Computer Readable Sequence Listing paper copy and diskette, and Declaration Pursuant to 37 C.F.R. §§ 1.821-1.825 for the above-referenced Application.

If questions arise, the undersigned may be contacted at (703) 836-6620.

In the event fees are required, the Commissioner is hereby authorized to charge the fees to PTO Deposit Account No. 02-4800.

Bv:

Respectfully submitted,

BUCHANAN INGERSOLL PC

(INCLUDING THE ATTORNEYS FROM BURNS DOANE SWECKER & MATHIS)

Date: <u>December 19, 2005</u>

Deborah H. Yellin

Registration No. 45,904

P.O. Box 1404 Alexandria, Virginia 22313-1404 (703) 836-6620



TENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE UNITED STATES DEPARTMENT OF COMMI United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Vagania 22313-1450 www.uspto.gov

ATTY. DOCKET NO. FIRST NAMED APPLICANT U.S. APPLICATION NUMBER NO. 017753-200 Manuel Rosa-Calatrava 10/520,626 INTERNATIONAL APPLICATION NO. PCT/IB03/03336 PRIORITY DATE I.A. FILING DATE Burns Doane Swecker & Mathis 07/10/2002 NAN INGERSOLL PC 07/10/2003 P O Box 1404 Alexandria, VA 22313-1404 **CONFIRMATION NO. 9366** OCT 26 2005 371 FORMALITIES LETTER DOCKETED *OC000000017 Date Mailed: 10/17/2005

NOTIFICATION TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant is given TWO MONTHS FROM THE DATE OF THIS NOTICE within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

The applicant needs to satisfy supplemental fees problems indicated below.

The following items MUST be furnished within the period set forth below in order to complete the requirements for acceptance under 35 U.S.C. 371:

 Additional claim fees of \$1250 as a non-small entity, including any required multiple dependent claim fee, are required. Applicant must submit the additional claim fees or cancel the additional claims for whigh fees URGERT are due.

SUMMARY OF FEES DUE:

Total additional fees required for this application is \$1250 for a Large Entity:

- This application does not contain a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). Applicant must provide such statement. If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000).
- A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 CFR 1.821(e). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000). Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.

- Total additional claim fee(s) for this application is \$ 1250
 - \$1250 for 25 total claims over 20.

Applicant is cautioned that correction of the above items may cause the specification and drawings page count to exceed 100 pages. If the specification and drawings exceed 100 pages, applicant will need to submit the required application size fee.

For questions regarding compliance to 37 CFR 1.821-1.825 requirements, please contact:

- For Rules Interpretation, call (571) 272-0951
- For Patentin Software Program Help, call Patent EBC at 1-866-217-9197 or directly at 703-305-3028 / 703-308-6845 between the hours of 6 a.m. and 12 midnight, Monday through Friday, EST.
- Send e-mail correspondence for Patentin Software Program Help @ ebc@uspto.gov

ALL OF THE ITEMS SET FORTH ABOVE MUST BE SUBMITTED WITHIN TWO (2) MONTHS FROM THE DATE OF THIS NOTICE OR BY 32 MONTHS FROM THE PRIORITY DATE FOR THE APPLICATION, WHICHEVER IS LATER. FAILURE TO PROPERLY RESPOND WILL RESULT IN ABANDONMENT.

The time period set above may be extended by filing a petition and fee for extension of time under the provisions of 37 CFR 1.136(a).

Applicant is reminded that any communications to the United States Patent and Trademark Office must be mailed to the address given in the heading and include the U.S. application no. shown above (37 CFR 1.5)

A copy of this notice MUST be returned with the response.

CHRISTINE S WASHINGTON

Telephone: (703) 308-9140 EXT 228

PART 1 - ATTORNEY/APPLICANT COPY

U.S. APPLICATION NUMBER NO.	INTERNATIONAL APPLICATION NO.	ATTY. DOCKET NO.
10/520,626	PCT/IB03/03336	017753-200

FORM PCT/DO/EO/922 (371 Formalities Notice)